Viatris operations interviews test whether candidates understand how managing pharmaceutical manufacturing and supply chain differs from industrial or chemical operations – where FDA's current Good Manufacturing Practice regulations under 21 CFR Parts 210 and 211 create mandatory quality system requirements for every aspect of pharmaceutical production including raw material testing, in-process controls, batch release testing, and deviation investigation that must be executed before a batch can be released for distribution, where active pharmaceutical ingredient supply chains concentrated in India and China create geopolitical and regulatory risk from foreign facility FDA inspection outcomes that can restrict API availability and trigger drug shortage notifications, and where the Drug Supply Chain Security Act's track-and-trace serialization requirements mandate unique product identifiers at the unit level that must be maintained through the full distribution chain to enable product verification and recall management. Operations at Viatris spans FDA cGMP manufacturing compliance (where Viatris's global manufacturing network including facilities in India, Ireland, Germany, and the United States must maintain FDA-registered and inspected status for each facility, respond to FDA Form 483 observations and Warning Letters with corrective action plans that address root causes rather than symptoms, and implement pharmaceutical quality systems that generate the batch records, out-of-specification investigation reports, and change control documentation that FDA inspectors review during surveillance inspections), API supply chain qualification and geographic risk management (where active pharmaceutical ingredient supply chains for Viatris's products typically include suppliers in India and China whose manufacturing facilities are subject to FDA inspection and whose supply reliability depends on their own cGMP compliance status – creating supply chain risk that Viatris must manage through supplier qualification programs, safety stock strategies, and dual-sourcing development for critical APIs where single-source dependency creates unacceptable supply disruption risk), drug shortage management and FDCA compliance (where Viatris as a significant generic pharmaceutical manufacturer has obligations under FDCA Section 506C to notify FDA at least six months in advance when a discontinuation or interruption of a product that is medically necessary and has no adequate alternative is anticipated), and pharmaceutical serialization and DSCSA compliance (where the Drug Supply Chain Security Act requires pharmaceutical manufacturers to affix a unique product identifier including the standardized numerical identifier, lot number, and expiration date on each sellable unit, and to exchange electronic transaction information with trading partners who receive the product for distribution or dispensing).

Start your free Viatris Operations practice session.

What interviewers actually evaluate

FDA cGMP Compliance, API Supply Chain Risk, and Drug Shortage Management

Viatris operations interviews probe whether candidates understand how pharmaceutical manufacturing management differs from industrial operations in the FDA regulatory relationship (unlike industrial operations where quality failures primarily create cost and customer service consequences, pharmaceutical cGMP failures create regulatory consequences including FDA Warning Letters that restrict distribution, consent decrees that impose third-party oversight of operations, and mandatory recalls for products released with quality defects that pose patient safety risk – where the operations manager who treats cGMP as a compliance burden rather than a patient safety obligation creates regulatory risk that can shut down manufacturing and create product unavailability for patients dependent on Viatris's products), the API supply concentration risk management imperative (the pharmaceutical industry's dependence on Indian and Chinese API manufacturers for the majority of generic drug active ingredient supply creates regulatory-driven supply disruption risk when FDA inspection findings at API suppliers result in import alerts that restrict the supplier's products from entering the US market – where Viatris's operations team must maintain qualification of alternative API sources for critical molecules and carry safety stock that can bridge supply disruptions long enough for alternative source qualification to be completed), and the drug shortage notification obligation (FDA's mandatory shortage notification requirement under FDCA Section 506C applies to Viatris as a manufacturer of drugs that may be medically necessary, creating an obligation to provide early warning to FDA when a supply disruption is anticipated that allows FDA to identify alternative manufacturers, coordinate with other stakeholders, and manage patient access to affected medications).

The EpiPen manufacturing and supply chain dimension creates operational responsibilities specific to Viatris's most visible branded product: EpiPen is a combination product with both a drug component (epinephrine solution) and a device component (the auto-injector mechanism), and any manufacturing defect, device quality failure, or supply chain disruption that affects EpiPen availability creates not just commercial consequences but patient safety risk for anaphylaxis patients who depend on reliable device availability and function. Operations at Viatris must maintain the supply continuity and device quality standards for EpiPen that patient safety requires while managing the manufacturing complexity of a combination product regulated under both drug and device quality system requirements.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
FDA cGMP compliance program management and Warning Letter response Do you understand how to manage Viatris's cGMP compliance program across global manufacturing facilities – what the pharmaceutical quality system elements are under 21 CFR Part 211 including deviation investigation, corrective and preventive action, change control, and annual product review that create the documented evidence base that FDA inspectors evaluate, how to structure the corrective action plan response to an FDA Form 483 observation that addresses root cause rather than just the specific observation cited, and how to manage operations during the period after a Warning Letter is issued when FDA requires demonstrated remediation before approving new product applications at the affected facility? We flag operations answers that treat FDA cGMP as a documentation exercise without engaging with the root cause investigation and systemic corrective action that distinguish genuine compliance programs from observation-by-observation responses that do not address underlying quality system deficiencies. CAPA root cause investigation, Form 483 response strategy, Warning Letter operational impact management
API supply chain qualification and geographic concentration risk Can you describe how to manage Viatris's API supply chain risk for products with India or China-concentrated API sourcing – how to structure the supplier qualification process for a new API source including site audits, quality agreement development, and FDA/ICH submission requirements for using a new API source in an existing approved product, what safety stock level methodology balances the cost of carrying inventory against the supply disruption probability and lead time for qualifying an alternative source, and how to develop the dual-sourcing roadmap for APIs where current single-source dependency creates unacceptable supply disruption risk given the API manufacturer's FDA compliance history? We score whether your API supply chain approach engages with the FDA submission requirements for alternative API source qualification and the safety stock strategy that bridges the qualification timeline when primary source disruption occurs. Alternative API source qualification FDA submission, safety stock optimization methodology, dual-source roadmap prioritization
Drug shortage notification and FDCA Section 506C compliance Do you understand how to manage Viatris's drug shortage notification obligations – what events trigger the six-month advance notification requirement to FDA under FDCA Section 506C for medically necessary drugs, how to assess whether a specific Viatris generic product meets the "medically necessary" threshold that triggers mandatory notification given the availability of therapeutic alternatives, and how to manage the FDA communication and monitoring process during an active shortage where FDA requires weekly updates on the supply situation and estimated resolution timeline? We detect operations answers that treat drug shortage notification as a regulatory form submission rather than an ongoing FDA engagement process that requires real-time communication about supply status and corrective action progress during active shortages. Section 506C notification trigger assessment, medically necessary product determination, active shortage FDA communication
DSCSA serialization and pharmaceutical supply chain security compliance Can you describe how to ensure Viatris's compliance with Drug Supply Chain Security Act serialization requirements – what the unit-level serialization requirements include in terms of the standardized numerical identifier composition (NDC, serial number, lot number, expiration date), how the electronic transaction information exchange requirement works when Viatris ships serialized product to a wholesale distributor and the distributor must verify the product's transaction history before reselling, and how to manage a serialization exception when a customer returns a product that lacks the required transaction history documentation that DSCSA requires for return processing? We flag operations answers that describe DSCSA as a labeling requirement without engaging with the electronic transaction data exchange and verification requirements that create supply chain partner compliance obligations throughout the distribution chain. SNI composition and serialization implementation, transaction data exchange with wholesale distributors, returned goods verification

How a session works

Step 1: Choose a Viatris operations scenario – FDA cGMP compliance program management and Warning Letter response, API supply chain qualification and geographic concentration risk, drug shortage notification and FDCA Section 506C compliance, or DSCSA serialization and pharmaceutical supply chain security compliance.

Step 2: The AI interviewer asks realistic Viatris-style questions: how you would manage the operations response when FDA issues a Form 483 during a surveillance inspection at Viatris's Morgantown West Virginia manufacturing facility with three observations – one relating to inadequate investigation of out-of-specification test results for a metformin batch, one relating to failure to include all process steps in the batch manufacturing record, and one relating to inadequate cleaning validation for equipment shared between two different product lines – including how you would prioritize the root cause investigation across the three observations, what corrective action plan structure you would propose in the 483 response, and how to assess whether the observations indicate systemic quality system failures that may warrant voluntary corrective action beyond the specific observations cited; how you would develop the API supply chain resilience plan for a Viatris generic product line whose primary API is sourced from a single Indian manufacturer that has received three FDA Warning Letters in the past five years – including what the qualification criteria are for a second API source, what the FDA DMF or ASMF submission requirements are for using a new API source in an existing approved product, and what safety stock level you would recommend carrying to bridge the alternative source qualification timeline if the primary API supplier receives an import alert; or how you would manage the mandatory drug shortage notification process when Viatris's primary manufacturer for a generic injectable antibiotic needs to shut down production for 90 days for equipment maintenance – including how to assess whether the product meets the medically necessary drug threshold, what information must be included in the FDA shortage notification, and how to coordinate with FDA's drug shortage staff during the 90-day shutdown to provide the update reporting FDA requires.

Step 3: You respond as you would in the actual interview. The system scores your answer on cGMP compliance management, API supply chain risk, drug shortage notification, and DSCSA compliance.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical operations expertise and what needs stronger FDA regulatory compliance specificity or API supply chain risk analysis.

Frequently Asked Questions

What are FDA's current Good Manufacturing Practice regulations for pharmaceutical manufacturers?
FDA's cGMP regulations under 21 CFR Parts 210 and 211 establish the minimum requirements for methods, facilities, and controls used in manufacturing, processing, packing, and holding of drug products to ensure they are safe, effective, and of consistent quality. The regulations require pharmaceutical manufacturers to maintain a quality control unit with authority and responsibility for approving or rejecting drug products, written procedures for all manufacturing and control operations, complete batch records documenting the manufacturing history of each batch, investigation of any out-of-specification laboratory result or unexplained discrepancy, and validation of critical manufacturing processes. FDA enforces cGMP compliance through routine surveillance inspections of registered pharmaceutical manufacturing facilities, and findings that represent significant compliance failures are documented in FDA Form 483 observations and, for more serious findings, FDA Warning Letters that require documented corrective action before FDA approves new drug applications at the affected facility.

What is the drug shortage notification requirement and when does it apply to Viatris?
FDCA Section 506C requires manufacturers of covered products – drugs and biological products that FDA determines are necessary to avoid a shortage – to notify FDA at least six months in advance of a discontinuation or a meaningful disruption of manufacturing. FDA uses the shortage notifications to identify potential supply gaps and coordinate with other manufacturers to increase supply of affected products. Viatris, as a manufacturer of many generic products that may be the sole or one of few available manufacturers for specific drugs, has ongoing obligations to monitor its supply situation and submit timely notifications when supply disruptions are anticipated. The six-month advance notice requirement is intended to provide FDA and the market with sufficient time to develop supply alternatives, though FDA recognizes that unexpected events may prevent full six-month advance notice in all cases.

How does FDA's import alert system affect Viatris's API supply chain?
FDA can place a pharmaceutical manufacturer's products on an import alert when the manufacturer has been found to have significant cGMP compliance violations that make their products appear to be manufactured under conditions that do not ensure safety and efficacy. When an API manufacturer receives an import alert, US pharmaceutical manufacturers like Viatris cannot receive API from that manufacturer unless they obtain an FDA exemption or the manufacturer successfully demonstrates remediation that leads to import alert removal. The potential for FDA import alerts at Indian or Chinese API suppliers creates ongoing supply chain risk for Viatris's generic portfolio, where many APIs are sourced from a concentrated group of manufacturers in those geographies. Viatris's supplier qualification and monitoring program includes regular assessments of API suppliers' FDA inspection history and import alert status.

What is DSCSA serialization and why does it matter for pharmaceutical supply chain operations?
The Drug Supply Chain Security Act, enacted in 2013, created a framework for pharmaceutical product tracing through the US supply chain with the goal of enabling product authentication and facilitating efficient recalls. The act requires pharmaceutical manufacturers to affix a standardized numerical identifier (including the National Drug Code, serial number, lot number, and expiration date) to each sellable unit of prescription drug product and to exchange electronic transaction information with trading partners who receive the product. Each time a serialized unit changes hands from manufacturer to wholesaler to pharmacy, the receiving party must verify the product's transaction information and maintain records that allow tracing the product's complete distribution history. For Viatris, DSCSA compliance requires maintaining serialization systems across all manufacturing lines, establishing electronic transaction data exchange with wholesale distributor trading partners, and managing the exception processes for situations where transaction history documentation is incomplete or unavailable.

How does Viatris manage manufacturing quality for EpiPen as a combination product?
EpiPen is regulated as a combination product because it consists of both a drug component (epinephrine solution) and a device component (the auto-injector mechanism that delivers the drug). FDA's Office of Combination Products coordinates oversight of combination products, and EpiPen's primary mode of action as a drug delivery system means it is primarily regulated under drug cGMP requirements with device quality system elements applied to the auto-injector component. Manufacturing quality requirements for EpiPen include drug product quality testing for the epinephrine solution including potency, sterility, and container closure integrity, device testing for the auto-injector mechanism including delivery force, dose accuracy, and needle deployment, and combination product-level testing that verifies the assembled EpiPen delivers the labeled epinephrine dose reliably under the use conditions that anaphylaxis patients experience. Device failures during clinical use that are reported through Viatris's pharmacovigilance system must be assessed as potential adverse events and quality complaints simultaneously, triggering both regulatory reporting and manufacturing investigation.

Also practice

One full session free. No account required. Real, specific feedback.